Iterum Therapeutics Plc (ITRM) has released an update to notify the public and investors about a regulation fd disclosure.
Iterum Therapeutics plc announced positive results from its Phase 3 REASSURE Clinical Trial for Oral Sulopenem in the treatment of uncomplicated urinary tract infections. The company issued a press release and provided an investor presentation, both of which are available on its website. This information, which is included in the current report, is furnished but not filed for legal and regulatory purposes and is not incorporated by reference into other filings.
For further insights into ITRM stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
